The leading ER+/ HER2 -ve Breast Cancer Companies such as AstraZeneca, Atossa Therapeutics, Inc., Accutar Biotechnology Inc, ...

If a deal is confirmed and consummated, Novartis would claim ownership of a biotech that has raised something of a stir in ...

Meanwhile, mRNA vaccine maker Moderna is cutting around 500 jobs (10% of its workforce) as part of a commitment to save $1.5 ...

--Novartis made a takeover approach for Avidity Biosciences, a biotechnology company that specializes in rare diseases with a market value of $5.8 billion, the Financial Times reports, citing unnamed ...

Millions of people are alive today because of leukemia therapies that arose from UC research, including retired Army Major ...

Avidity Biosciences stock rocketed Wednesday on a report Novartis made an attempt to buy the rare disease-focused biotech ...

The US Food and Drug Administration approved the revised label for inclisiran, a small interfering RNA that reduces the ...

By Twesha Dikshit and Ragini Mathur (Reuters) -European shares closed flat on Wednesday, surrendering early session gains, as ...

Avidity Biosciences ( NASDAQ: RNA) quickly soared 20% after a report that Novartis ( NYSE: NVS) made a takeover approach for the rare-disease maker.

Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times ...

The FDA has approved a labeling update for Leqvio (inclisiran) allowing for first-line use in the treatment of hypercholesterolemia.

A novel way to prevent the spread of malaria – a potentially life-threatening disease transmitted through bites from ...